This CME/CE program will outline recent advances in the treatment and management of patients with metastatic breast cancer. The expert faculty, led by Dr. Harold J. Burstein, will first cover ER-positive breast cancer, analyzing data for CDK 4/6 inhibitors, ER targeting agents and antibody drug conjugates. Following, pertinent information regarding triple negative breast cancer will be reviewed, highlighting clinical implication for practice. The faculty will conclude with an overview of recent clinical trials in the HER2 positive metastatic breast cancer treatment landscape. Upon conclusion of this discussion-based education, clinicians will gain further insight into how to apply current data regarding metastatic breast cancer to practice.
Oncologists, OB-GYNs, breast surgeons, general surgeons, physician assistants, nurse practitioners, oncology nurses, oncology pharmacists, and all other HCPs involved in the management of patients with breast cancer
- Review and analyze the latest therapeutic advances for the treatment and management of breast cancer as presented and explored at SABCS 2021
- Apply new data and therapeutic advances into guideline-driven treatment strategies to improve the care of patients with breast cancer, including-where appropriate-with COVID-19 considerations
I. ER-Positive Breast Cancer – Erika P. Hamilton, MD
II. Triple Negative Breast Cancer – Joyce A. O’Shaughnessy, MD
III. HER2-Positive Breast Cancer – Harold J. Burstein Jr., MD, PhD
IV. Interactive Expert Panel Discussion – All Faculty
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Harold J. Burstein, MD, PhD (Course Chair)||Nothing to disclose|
|Erika P. Hamilton, MD||Consultant/Advisor: Arrcus Inc.; Arvinas; AstraZeneca Pharmaceuticals; Black Diamond; Boehringer Ingelheim International GmbH; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dantari; Deciphera Pharmaceuticals, Inc.; Eli Lilly and Company; Eisai Co., Ltd.; Genentech, Inc.; H3 Biomedicine Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Loxo Oncology; Merck & Co., Inc.; Mersana Therapeutics; Novartis AG; Pfizer Inc.; Puma Biotechnology; Relay Therapeutics; Roche; Silverback Therapeutics
Research/Grant Support: AbbVie, Inc.; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive Inc.; ArQule, Inc.; Arvinas; AstraZeneca Pharmaceuticals; AtlasMedx, INC.; Black Diamond; Boehringer Ingelheim International GmbH; Clovis Oncology; Compugen; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana Farber Cancer Institute; Deciphera Pharmaceuticals, Inc.; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Eli Lilly and Company; EMD Serono Inc.; Fochon Pharmaceuticals Ltd.; FujiFilm; G1 Therapeutics; Genentech, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; Hutchison MediPharma Ltd; ImmunoGen, Inc.; Immunomedics; Incyte Corporation; InventisBio; Jacobio Pharmaceuticals; Karyopharm; Leap Therapeutics, Inc.; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune; Merck & Co., Inc.; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Myraid Genetic Laboratories; Novartis AG; NuCana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics Inc.; ORIC Pharmaceuticals; Orinove Inc.; PharmaMar; Pfizer Inc.; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health; Regeneron Pharmaceuticals Inc.; Repertoire Immune Medicine; Rgenix; Roche; Seattle Genetics; Sermonix Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; StemCentRx; Sutro Biopharma, Inc.; Syndax Pharmaceuticals Inc.; Syros Pharmaceuticals, Inc.; Taiho Pharmaceutical Co., Ltd.; TapImmune; Tesaro, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; Zenith Epigenetics; Zymeworks
|Joyce A O’Shaughnessy, MD
|Consultant/Advisor: AbbVie, Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca Pharmaceuticals; Bayer AG; Bristol-Myers Squibb Company; Carrick Therapeutics; Celgene Corporation; Clovis Oncology; Daiichi Sankyo, Inc.; Eisai Co., Ltd.; Eli Lilly and Company; G1 Therapeutics; Genentech, Inc.; Gilead Sciences; GRAIL; Halozyme Therapeutics; Heron Therapeutics; Immunomedics; Ipsen Biopharmaceuticals; Merck & Co., Inc.; Myraid Genetic Laboratories; Nektar Therapeutics; Novartis AG; Ontada LLC; Pfizer Inc.; Pharmacyclics LLC; Pierre Fabre Pharmaceuticals; Puma Biotechnology; Prime Oncology; Roche; Samsung Bioepis; Sanofi-Aventis U.S. LLC; Seagen Inc.; Syndax Pharmaceuticals Inc.; Synthon; Taiho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Company Limited|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 80% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].